The Journal of Contemporary Dental Practice

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  25 (2024)
Volume  24 (2023)
Volume  23 (2022)
Volume  22 (2021)
Volume  21 (2020)
Volume  20 (2019)
Volume  19 (2018)
Volume  18 (2017)
Volume  17 (2016)
Volume  16 (2015)
Volume  15 (2014)
Volume  14 (2013)
Volume  13 (2012)
Volume  12 (2011)
Volume  11 (2010)
Volume  10 (2009)
Volume  9 (2008)
Volume  8 (2007)
Volume  7 (2006)
Volume  6 (2005)
Volume  5 (2004)
Volume  4 (2003)
Volume  3 (2002)
Volume  2 (2001)
Volume  1 (1999)
Related articles

VOLUME 13 , ISSUE 2 ( March-April, 2012 ) > List of Articles

RESEARCH ARTICLE

Comparison of COX2 Expression between Oral Squamous Cell Carcinoma, Leukoplakia and Normal Mucosa

Maryam Amirchaghmaghi, Nooshin Mohtasham, Pegah Mosannen Mozaffari

Citation Information : Amirchaghmaghi M, Mohtasham N, Mozaffari PM. Comparison of COX2 Expression between Oral Squamous Cell Carcinoma, Leukoplakia and Normal Mucosa. J Contemp Dent Pract 2012; 13 (2):205-209.

DOI: 10.5005/jp-journals-10024-1122

Published Online: 01-10-2012

Copyright Statement:  Copyright © 2012; The Author(s).


Abstract

Aim

To compare cyclooxygenase 2 expression (COX2-E) between normal, oral leukoplakia lesions and different grades of oral squamous cell carcinoma (SCC).

Materials and methods

Around 90 paraffin embedded blocks consisting of 45 SCC, 15 leukoplakia and 17 controls were selected for immunohistochemistry (IHC) for detection of COX2- E. COX2-E was divided in four grades, as A (0-10%), B (11-40%), C (41-70%) and D (> 70%) cellularity.

Results

Mean age of the patients was 55.17 ± 18.41 (M:57.92 ± 16.87, F:52.19 ± 19.74). A significant difference was found in COX2 expression between SCC total and, basal and spinous layers of leukoplakia (p < 0.05). COX2-E in spinous layer of normal tissue was significantly lower than SCC (p = 0.000). COX2-E was significantly different in SCC grade 3 and leukoplakia (p = 0.001) and normal tissue (p = 0.000). COX2-E was significantly higher in SCC grade 3 compared to leukoplakia (basal layer) (p = 0.000).

Conclusion

We showed a significant higher COX2-E in SCC lesions compared to leukoplakias and normal controls. In our study COX2-E was not significantly different in SCC grades 1, 2 and 3 (p > 0.05).

How to cite this article

Amirchaghmaghi M, Mohtasham N, Mozaffari PM. Comparison of COX2 Expression between Oral Squamous Cell Carcinoma, Leukoplakia and Normal Mucosa. J Contemp Dent Pract 2012;13(2):205-209.

PDF Share
  1. Clinical and histopathological analysis of oral squamous cell carcinoma of young patients in Mashhad, Iran: A retrospective study and review of literatures. Medicina Oral, Patologia Oraly Cirugia Bucal 2010.
  2. Oral squamous cell carcinoma in a young patient: Case report and literature review. Anais Brasileiros de Dermatologia 2006;81(3):251-54.
  3. Risk factors for oral cancer in newly diagnosed patients aged 45 years and younger: A case–control study in Southern England. Journal of Oral Pathology and Medicine 2004;33(9):525-32.
  4. Clinicopathological features of squamous cell carcinoma of the oral cavity in patients < 40 years of age. Journal of Oral Pathology and Medicine. 2005;34(3):129-33.
  5. Cancer incidence and mortality in Iran. Annals of Oncology 2009;20(3):556.
  6. Expression of cyclooxygenase 2 and microsomal prostaglandin E synthase in amoeboid microglial cells in the developing brain and effects of cyclooxygenase 2 neutralization on BV 2 microglial cells. Journal of Neuroscience Research 2010;88(7):1577-94.
  7. The effects of a COX2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo. International Journal of Cancer 2008;122(7):1639-44.
  8. Expression of cyclooxygenase-2 and microsomal prostagalandin E synthase-1 in head and neck squamous cell carcinoma. Auris Nasus Larynx 2010;37(4):482-87.
  9. Overexpression of COX-2 gene in oral cancer is independent of stage of disease and degree of differentiation. International Journal of Oral and Maxillofacial Surgery 2008;37(4):379-83.
  10. Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. American Journal of Otolaryngology 2009;30(2):89-94.
  11. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anti-Cancer Drugs 2002;13(2):127.
  12. Cyclooxygenases in cancer: Progress and perspective. Cancer Letters 2004;215(1):1-20.
  13. HSP 27 as possible prognostic factor in patients with oral squamous cell carcinoma. Histology and Histopathology 2004;19(1):119-28.
  14. Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma. Advances in Therapy 2006;23(5):672-79.
  15. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1 Mar 1999;59(5):991-94.
  16. The effect of nitric oxide on cyclooxygenase 2 (COX2) overexpression in head and neck cancer cell lines. International Journal of Cancer 2003;107(5):729-38.
  17. The expression of heat shock proteins 27 and 105 in squamous cell carcinoma of the tongue and relationship with clinicopathological index. Med Oral Patol Oral Cir Bucal 2011.
  18. COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Modern Pathology 2004;18(1):153-60.
  19. Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus; An immunohistochemical survey. Anticancer Res Jan-Feb 1999;19(1A):171-74.
  20. Expression of cyclooxygenase-2 in human tongue carcinoma and its precursor lesions. Virchows Archiv 2002;440(6):594-97.
  21. Expression of cyclooxygenase-1and-2 in human colorectal cancer. Cancer Res 1995;55(17):3785.
  22. COX2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89(12):2637-45.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.